Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily S J Edwards

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
The Journal of Allergy and Clinical Immunology|December 26, 2024
Update on inborn errors of immunityHanna IJspeert, Emily S J Edwards, Robyn E O'Hehir, et al.
Frontiers in Immunology|February 4, 2022
Common Variable Immunodeficiency Disorders as a Model for Assessing COVID-19 Vaccine Responses in Immunocompromised PatientsRohan Ameratunga, See-Tarn Woon, Richard Steele, et al.
Chemmedchem|March 13, 2020
Synthesis and Biological Evaluation of Hapten-Clicked Analogues of The Antigenic Peptide Melan-A/MART-1<sub>26(27L)-35</sub>Marion Tarbe, John J Miles, Emily S J Edwards, et al.
The Journal of Allergy and Clinical Immunology|May 21, 2023
Combined immunodeficiency and impaired PI3K signaling in a patient with biallelic LCP2 variantsEmily S J Edwards, Samar Ojaimi, James Ngui, et al.
Journal of Clinical Immunology|October 20, 2025
Novel SYK Variant Causes Enhanced SYK Autophosphorylation and PI3K Activation in an Antibody-Deficient PatientEmily S J Edwards, Josh Chatelier, Gregory I Snell, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 16, 2023
The Rapidly Expanding Genetic Spectrum of Common Variable Immunodeficiency-Like DisordersRohan Ameratunga, Emily S J Edwards, Klaus Lehnert, et al.
Frontiers in Immunology|December 6, 2019
Predominantly Antibody-Deficient Patients With Non-infectious Complications Have Reduced Naive B, Treg, Th17, and Tfh17 CellsEmily S J Edwards, Julian J Bosco, Pei M Aui, et al.
Allergy|December 21, 2022
The second COVID-19 mRNA vaccine dose enhances the capacity of Spike-specific memory B cells to bind Omicron BA.2Gemma E Hartley, Emily S J Edwards, Nirupama Varese, et al.
Journal of Clinical Immunology|June 15, 2023
COVID-19 Adenoviral Vector Vaccination Elicits a Robust Memory B Cell Response with the Capacity to Recognize Omicron BA.2 and BA.5 VariantsHolly A Fryer, Gemma E Hartley, Emily S J Edwards, et al.
NPJ Vaccines|July 16, 2024
Homologous but not heterologous COVID-19 vaccine booster elicits IgG4+ B-cells and enhanced Omicron subvariant bindingGemma E Hartley, Holly A Fryer, Paul A Gill, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
The Journal of Allergy and Clinical Immunology|December 26, 2024
Update on inborn errors of immunityHanna IJspeert, Emily S J Edwards, Robyn E O'Hehir, et al.
Frontiers in Immunology|February 4, 2022
Common Variable Immunodeficiency Disorders as a Model for Assessing COVID-19 Vaccine Responses in Immunocompromised PatientsRohan Ameratunga, See-Tarn Woon, Richard Steele, et al.
Chemmedchem|March 13, 2020
Synthesis and Biological Evaluation of Hapten-Clicked Analogues of The Antigenic Peptide Melan-A/MART-1<sub>26(27L)-35</sub>Marion Tarbe, John J Miles, Emily S J Edwards, et al.
The Journal of Allergy and Clinical Immunology|May 21, 2023
Combined immunodeficiency and impaired PI3K signaling in a patient with biallelic LCP2 variantsEmily S J Edwards, Samar Ojaimi, James Ngui, et al.
Journal of Clinical Immunology|October 20, 2025
Novel SYK Variant Causes Enhanced SYK Autophosphorylation and PI3K Activation in an Antibody-Deficient PatientEmily S J Edwards, Josh Chatelier, Gregory I Snell, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 16, 2023
The Rapidly Expanding Genetic Spectrum of Common Variable Immunodeficiency-Like DisordersRohan Ameratunga, Emily S J Edwards, Klaus Lehnert, et al.
Frontiers in Immunology|December 6, 2019
Predominantly Antibody-Deficient Patients With Non-infectious Complications Have Reduced Naive B, Treg, Th17, and Tfh17 CellsEmily S J Edwards, Julian J Bosco, Pei M Aui, et al.
Allergy|December 21, 2022
The second COVID-19 mRNA vaccine dose enhances the capacity of Spike-specific memory B cells to bind Omicron BA.2Gemma E Hartley, Emily S J Edwards, Nirupama Varese, et al.
Journal of Clinical Immunology|June 15, 2023
COVID-19 Adenoviral Vector Vaccination Elicits a Robust Memory B Cell Response with the Capacity to Recognize Omicron BA.2 and BA.5 VariantsHolly A Fryer, Gemma E Hartley, Emily S J Edwards, et al.
NPJ Vaccines|July 16, 2024
Homologous but not heterologous COVID-19 vaccine booster elicits IgG4+ B-cells and enhanced Omicron subvariant bindingGemma E Hartley, Holly A Fryer, Paul A Gill, et al.
Pageof 4